Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...

The results suggest Ozempic could potentially become a new alternative treatment for opioid use disorder, which could help ...

Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global ...

Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.